These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24871500)

  • 1. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.
    Montravers P; Dupont H; Bedos JP; Bret P;
    Intensive Care Med; 2014 Jul; 40(7):988-97. PubMed ID: 24871500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
    Maseda E; Denis SE; Riquelme A; Gilsanz F
    Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Differences in the use of tigecycline between ICU patients and non-ICU patients].
    Alvarez-Lerma F; Blanco L; Rodríguez JA; Grau S; Conde-Estévez D; Luque S
    Rev Esp Quimioter; 2010 Jun; 23(2):63-71. PubMed ID: 20559603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
    Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tigecycline use in serious nosocomial infections: a drug use evaluation.
    Bassetti M; Nicolini L; Repetto E; Righi E; Del Bono V; Viscoli C
    BMC Infect Dis; 2010 Sep; 10():287. PubMed ID: 20920273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
    Mouloudi E; Massa E; Piperidou M; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Kydona C; Fouzas I; Imvrios G; Papanikolaou V; Gritsi-Gerogianni N
    Transplant Proc; 2014 Nov; 46(9):3219-21. PubMed ID: 25420864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
    Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY
    Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
    Kuo SC; Wang FD; Fung CP; Chen LY; Chen SJ; Chiang MC; Hsu SF; Liu CY
    J Microbiol Immunol Infect; 2011 Feb; 44(1):45-51. PubMed ID: 21531352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tigecycline for treatment of severe infections in intensive care: a drug use evaluation].
    Jung B; Chanques G; Ghiba M; Cisse M; Rossel N; Perrigault PF; Souche B; Jean-Pierre H; Jaber S
    Ann Fr Anesth Reanim; 2010 May; 29(5):354-60. PubMed ID: 20347565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
    Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
    Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
    Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
    Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights.
    Ibrahim MM; Abuelmatty AM; Mohamed GH; Nasr MA; Hussein AK; Ebaed MED; Sarhan HA
    Drug Des Devel Ther; 2018; 12():4171-4179. PubMed ID: 30584281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
    Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
    Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.